CBD Nutraceuticals Industry Market To Grow With New Study Showing Cannabinoids Might Reduce Secondary Damage Of Traumatic Brain Injury

  • Analysis
  • 25-May-2021

Patients need to be vigilant for hours or even days after a Traumatic Brain Injury (TBI) as the inflammation inside the brain can accelerate to the degree that can lead to more brain damage. Researchers have tried to understand this acceleration for a long time and whether interventions like cannabinoids result in better patient outcomes or not. Some TBI patients are known to inherently do well, while most need therapy to balance the vigorous inflammation required to clean up the site in the aftermath of any injury. It is also beneficial for deceleration necessary to complete the healing and avoid brain damage. Typically, neither medical nor surgical intervention can control the inflammation to restrict secondary destruction; thus, further research is needed on the topic to provide better treatment.
Recent research has broached this problem by exploring the role of the body’s endocannabinoid system. The team is set to use a combination of both the research drug that inhibits MAGL and the cannabinoid CBD. They have primary evidence that cannabinoid CBD also inhibits MAGL, and the research further explores the subject. The study is a considerable contribution towards the CBD Nutraceuticals Industry Market as it will investigate the early inhibition of MAGL in immune cells regarding the research drug, cannabinoids CBD, and other commercially produced versions of endocannabinoids 2-AG and AEA. In addition, it will look into the effect on the enzyme’s apparent natural predisposition to augment inflammation resulting after a TBI. This might reveal the best way to reduce secondary damage in TBI, thus reducing the number of deaths that are caused by it.
Researchers believe that problem revolves around the high MAGL, which degrades 2-AG before it can even do its job of being anti-inflammatory. They stated that high MAGL levels lead to increased inflammation after TBI. The team revealed through their evidence that decreasing MAGL levels could ensure healthy synergy between the cannabinoid receptor CB2, MAGL, and 2-AG, thus making it a key point for intervention.
They will investigate the best place to intervene and if research drug or CBD would be best applicable to do it. In addition, the team also needs to find the optimal time for an intervention. This is because the process cannot impede the initial aggressive immune response that is required to clean up the injury. It has been discovered that MAGL and 2-AG levels are both quite low inside a cell, including immune cells. MAGL only degrades 2-AG if too much of it is produced for one reason or another, whereas 2-AG helps keep inflammation at bay.
TBI causes disabilities in more than 5 million Americans. As per the Centers for Disease Control and Prevention, falls are the most common reason for TBI, especially in older adults and kids. Moreover, incidents of falls account for about half of TBI-related visits to the emergency departments. Hence, this new research would be widely beneficial for the whole medical sector as it helps in better recovery after TBI-related incidents.

Other Related Reports:

Global Nutraceuticals Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast Till 2026

Global Constipation Nutraceuticals Market Growth 2020-2025

Global CBD Gummies Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast Till 2027

Global CBD Oil Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast Till 2027